Fiocruz scientists detects novel alterations in the Sars-CoV-2 Spike protein in Brazil

29 March 2021
fiocruz_big

Scientists at the Fiocruz Genomics Network have identified important changes in the Spike (S) protein structure of the Sars-CoV-2 virus circulating in Brazil.

Eleven gene sequences s howed deletions (loss of genetic material) in the initial region of the protein and in four there was some amino acids insertion. The Spike protein is associated with the pathogen's ability to enter human cells and is one of the main targets of the neutralizing antibodies produced by the body to block the virus.

The institution says that one of the effects of this change is contributing to maintaining the critical scenario in the occupation of hospital beds. The greater presence of young people admitted to hospitals is reported by health professionals from different regions. This week's Fiocruz bulletin translates this impression into numbers, notes a report by The Rio Times. Cases in Brazil among young people has increased sixfold, the newspaper stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight